Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
FGI Industries (FGI)
Verdant Earth Technologies (VDNT)
Modular Medical (MODD)
Jupiter Neurosciences, Inc. (JUNS)
Sunfire Acquisition (SUNFU)
Rhodium Enterprises, Inc. (RHDM)
Four Springs Capital Trust (FSPR)
Samsara Vision (SMSA)
Priced IPO
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
Amylyx Pharmaceuticals, Inc. (AMLX)
Cincor Pharma, Inc. (CINC)
Apptech (APCX)
NexGel, Inc. (NXGL)
Immix Biopharma (IMMX)
Bionomics Limited (BNOX)
Genenta Science (GNTA)
Samsara Inc. (IOT)
Sidus Space (SIDU)
Fresh Vine Wine, Inc. (VINE)
Nu Holdings Ltd. (NU)
Hashicorp, Inc. (HCP)
NeuroSense Therapeutics Ltd. (NRSN)
Cingulate, Inc. (CING)
Chicago Atlantic Real Estate Finance, Inc. (REFT)
More companies

Genenta Science (GNTA)

Sector - Healthcare

Price chart

-11.3%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. They have developed a novel biologic platform which involves the ex-vivo gene transfer of a therapeutic candidate into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Their technology is designed to turn TEMs, which normally have an affinity for and travel to tumors, into a “Trojan Horse” to counteract cancer progression and to prevent tumor relapse. Their technology is not target dependent, and therefore they believe it can be used as a treatment for a broad variety of cancers. Their technology incorporates the use of a lentiviral vector (LVV) that combines a therapeutic transgene sequence, or payload, with their proprietary platform. Their proprietary platform consists of (i) the Tie-2 promoter, that drives transgene sequence transcription specifically in TEMs, and (ii) miRNA-126 target sequences to downregulate transgene expression post-transcription in those cells where the Tie-2 promoter is active and the miRNA-126 is present.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
-
Employees Founded
4 2014

Contacts

Address: Via Olgettina No. 58 20132 Milan, Italy

Telephone: +39-02-2643-4681

Web page: http://www.genenta.com

IPO information

First Trade Date 12/15/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 2.6
Shares Revised (MM) 3.1
Expected offer amount (MM) $35
Realized offer amount(MM) $35.65

Financial Data (last reporting year)

Market Cap (MM) $202.52
Revenues (MM) $0
Net Income (Loss) (MM) $-8.0

Voting

What do you think will happen with the GNTA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Roth Capital

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Roth Capital
CO-Managers
Maxim Group LLC

Sector: Healthcare

Tweets about $GNTA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats